Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 16
2003 14
2004 12
2005 16
2006 8
2007 8
2008 5
2009 7
2010 9
2011 15
2012 11
2013 12
2014 10
2015 15
2016 17
2017 21
2018 14
2019 15
2020 29
2021 30
2022 25
2023 25
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

303 results

Results by year

Filters applied: . Clear all
Page 1
Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Tazoe K, Harada N, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Hirose A, Nakamae M, Nishimoto M, Nakashima Y, Koh H, Hino M, Nakamae H. Tazoe K, et al. Among authors: hino m. Ann Hematol. 2024 Apr 25. doi: 10.1007/s00277-024-05772-2. Online ahead of print. Ann Hematol. 2024. PMID: 38662207
Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation.
Takemura K, Nakamae M, Okamura H, Sakatoku K, Ido K, Makuuchi Y, Kuno M, Takakuwa T, Hirose A, Nishimoto M, Nakashima Y, Koh H, Igarashi K, Kubota H, Hino M, Nakamae H. Takemura K, et al. Among authors: hino m. Ann Hematol. 2024 May;103(5):1705-1715. doi: 10.1007/s00277-024-05685-0. Epub 2024 Mar 18. Ann Hematol. 2024. PMID: 38494552
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, Hotta M, Fuchida SI, Kanda J, Uoshima N, Shimura Y, Tanaka H, Ohta K, Kosugi S, Yagi H, Yoshihara S, Yamamura R, Adachi Y, Hanamoto H, Shibayama H, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M; Kansai Myeloma Forum. Nakamura N, et al. Among authors: hino m. Ann Hematol. 2024 Mar 16. doi: 10.1007/s00277-024-05705-z. Online ahead of print. Ann Hematol. 2024. PMID: 38492020
Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-leukemia Effects via HLA-B Leader in HLA-haploidentical Peripheral Blood Stem Cell Transplantation.
Moriguchi M, Ido K, Okamura H, Nakamae M, Sakatoku K, Makuuchi Y, Kuno M, Takakuwa T, Hirose A, Nishimoto M, Nakashima Y, Koh H, Hino M, Nakamae H. Moriguchi M, et al. Among authors: hino m. Acta Haematol. 2024 Mar 1. doi: 10.1159/000538078. Online ahead of print. Acta Haematol. 2024. PMID: 38432202
A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
Hirose A, Koh H, Nakamae M, Nakashima Y, Nishimoto M, Okamura H, Makuuchi Y, Kuno M, Takakuwa T, Ido K, Sakatoku K, Hino M, Nakamae H. Hirose A, et al. Among authors: hino m. Bone Marrow Transplant. 2024 May;59(5):695-698. doi: 10.1038/s41409-024-02231-4. Epub 2024 Feb 14. Bone Marrow Transplant. 2024. PMID: 38355910 No abstract available.
Comparison of long-term outcomes after first HLA-mismatched unrelated donor transplantation with single unrelated cord blood transplantation using reduced-intensity or reduced-toxicity conditioning.
Kuno M, Koh H, Ido K, Sakatoku K, Makuuchi Y, Takakuwa T, Hirose A, Okamura H, Nishimoto M, Nakashima Y, Nakamae M, Hino M, Nakamae H. Kuno M, et al. Among authors: hino m. Transpl Immunol. 2024 Feb;82:101988. doi: 10.1016/j.trim.2024.101988. Epub 2024 Jan 5. Transpl Immunol. 2024. PMID: 38185390
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, Hino M, Doki N, Nishida T, Ohigashi H, Matsuoka KI, Kanda Y, Maruyama Y, Sawa M, Eto T, Hiramoto N, Fukuda T, Atsuta Y, Nakamae H. Nakaya Y, et al. Among authors: hino m. Transplant Cell Ther. 2024 Mar;30(3):316.e1-316.e12. doi: 10.1016/j.jtct.2023.10.021. Epub 2023 Oct 30. Transplant Cell Ther. 2024. PMID: 38108263
303 results